首页
期刊简介
编 委 会
期刊订阅
百年学会 医星璀璨
名院风范
学科风华
菁英风采
投稿须知
过刊浏览
联系我们
篇名
关键词
作者
作者单位
摘要
关键词
注册本刊作者
作者投稿查稿
专家远程审稿
编辑在线审稿
编务办公专区
主编办公专区
下载文档
《上海医学》审稿费代缴委托书
《上海医学》杂志2024年征订启事
《上海医学》期刊编审系统审稿专家使用手册
工作动态
03-05
《上海医学》杂志2024年度“春蕾杯”论文评比征文通知
06-14
创新驱动,培育人才—《上海医学》2021年度春蕾计划评审结果揭晓
01-21
《上海医学》期刊影响力指标和学科排名取得显著提升
01-20
《上海医学》恭祝大家新年快乐!
08-18
作废声明
联系方式
发行周期:
月刊
主管单位:
上海市卫生健康委员会
主办单位:
上海市医学会
编辑出版:
《上海医学》编辑部
联系地址:
上海市北京西路1623号
邮编:
200040
电话:
021-62178606
传真:
021-62178606
邮箱:
smasmj@shsma.org.cn
ISSN:
ISSN0253-9934
CN:
CN31-1366/R
收款账号:
1001255309008900719
账户名:
上海市医学会
开户行:
工商银行上海市静安寺支行
友情链接
上海市医学会
当前位置:首页 >
雄激素调节基因WDR19在前列腺癌中的表达
浏览(620) 下载(0)
DOI:
作者:
盛璐
sheng lu
作者单位:
复旦大学附属华东医院
huadong hospital,fudan university
关键词:
雄激素调节蛋白WDR19,前列腺癌
WDR19, prostate cancer
摘要:
目的:评估一种新的雄激素调节蛋白WDR19(WD-重复蛋白19)在前列腺癌免疫组化检验中的研究价值。 材料与方法:随访本科前列腺癌根治标本25例及源于美国联合前列腺癌组织样本库(CPCTR)前列腺癌标本162例,对照良性前列腺增生标本15例,正常前列腺组织标本13例,通过高密度组织微阵列(tissue microarrays TMA)技术和部分临床病理再切片进行WDR19免疫组化染色研究。对染色标本进行染色浓度评分,分为阴性(0分),弱阳性(2分),中阳性(3分),强阳性(4分),以定量+定性评价WDR19免疫组化染色诊断前列腺癌的特异性与敏感性。结果行统计学分析。 结果: 187例前列腺癌病例年龄57-75岁(70±3.3岁)。Gleason评分<7分53例,=7分97例,>7分37例。前列腺癌组中,WDR19染色阴性8.56%(16/187), 弱阳性44.92%(84/187),中、强阳性46.52%(87/187);良性前列腺增生组中,WDR19染色阴性40%(6/15), 弱阳性60%(9/15),中、强阳性0%(0/15);正常前列腺组中,WDR19染色阴性38.46%(5/13), 弱阳性53.85%(7/13),中阳性7.69%(1/13)。前列腺癌组与BPH及正常前列腺组染色评分有显著性差异(P<0.001),而后两者间无显著性差异。 结论:WDR19可以成为前列腺癌免疫组化诊断的新酶标,其临床价值应予进一步研究。
Objective: To evaluate a new androgen regulated gene WDR19 (WD-repeat protein 19) in prostate cancer via immunohistochemical tests. Materials and Methods: 25 cases in follow-up of consecutive radical prostatectomy specimens and 162 cases of prostate cancer tissue samples from the Cooperative Prostate Cancer Tissue Resource (CPCTR) with control of 15 benign prostatic hyperplasia specimens and 13 normal prostate tissue samples. Using high-density tissue microarray (TMA) technique and WDR19 immunohistochemical tests. Concentration of stained specimens were scaled with negative (0), weakly positive (2 points), positive (3 points), strongly positive (4 points). The specificity and sensitivity of WDR19 immunohistochemical staining in diagnosis of prostate cancer were evaluated both quantitatively and qualitatively. Data was statistically analyzed using SAS software. Results: 187 cases of prostate cancer patients were 57-75 years old (70 ± 3.3 years). Gleason score < 7 in 53 cases, 7 points: 97 cases, > 7 points: 37 cases. In the prostate cancer group, 8.56% (16 / 187) were WDR19 negative, 44.92% (84/187) weakly positive, 46.52% (87/187) strong positive; while in the benign prostatic hyperplasia group, 40% (6/15) were WDR19 negative, 60% (9/15) weakly positive, 0% (0/15) strong positive; and in the normal prostate group, 38.46% (5/ 13) were WDR19 negative, 53.85% (7 / 13) weakly positive, 7.69% (1/13) positive. BPH and prostate cancer and normal prostate group staining scores were significantly different (P <0.001), there was no significance between the later two groups. Conclusion: WDR19 enzyme may be a new immunohistochemical diagnostic candidate for prostate cancer, and its clinical value should be further studied.
点击下载DOC全文